瑞德西韦

Description

Remdesivir · CAS 1809249-37-3 · C27H35N6O8P. UNII 3QKI37EEHE.

Identification

CAS Registry Number	1809249-37-3
PubChem CID	121304016
Molecular formula	C27H35N6O8P
IUPAC name	2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
UNII (FDA)	3QKI37EEHE

Computed Descriptors

Molecular Weight	602.6
XLogP3	1.9
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	13
Rotatable Bond Count	14
Exact Mass	602.22539909
Monoisotopic Mass	602.22539909
Topological Polar Surface Area	204
Heavy Atom Count	42
Formal Charge	0

GHS Hazard Classification

Reported hazard statements	H302 (33.3%), H315 (33.3%), H319 (33.3%), H335 (33.3%), H372 (33.3%), H373 (66.7%)

Documented Uses

• Remdesivir is indicated for the treatment of adult and pediatric patients 28 days of age and older and weighing at least 3 kg for coronavirus disease 2019 (COVID-19) infection requiring hospitalization. It is also indicated for the treatment of non-hospitalized patients with mild-to-moderate COVID-19, who are at high risk for progression to severe COVID-19, including hospitalization or death. Remdesivir was originally granted FDA Emergency Use Authorization (EUA) on May 1, 2020, for use in adults and children with
• Remdesivir is an antiviral nucleotide analogue used for therapy of severe novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS) coronavirus 2 (CoV-2) infection. Remdesivir therapy is given intravenously for 3 to 10 days and is frequently accompanied by transient, reversible mild-to-moderate elevations in serum aminotransferase levels but has been only rarely linked to instances of clinically apparent liver injury, its hepatic effects being overshadowed by the systemic effects
• Breast Feeding; Lactation; Milk, Human; Antimetabolites; Antiviral Agents
• Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033)
• Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
• Established Pharmacologic Class [EPC] - SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor

Synonyms

Remdesivir; 1809249-37-3; Veklury; GS-5734; 3QKI37EEHE; remdesivirum; GS 5734; GS5734; Remdesivir [USAN]; CHEBI:145994; DTXSID701022537; RefChem:6679; 13C3 GS-5734; 13C3-GS-5734; GS-465124; GS-829143

Frequently Asked Questions

What are the CAS number and molecular formula of Remdesivir?

CAS 1809249-37-3; molecular formula C27H35N6O8P; molecular weight — g/mol.

What other names is Remdesivir known by?

Remdesivir, 1809249-37-3, Veklury, GS-5734, 3QKI37EEHE, remdesivirum.

Is Remdesivir classified as hazardous?

Hazard statements reported: H302, H315, H319, H335, H372.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.